Goserelin

What it is

Goserelin (Zoladex) is a monthly or quarterly injection that dramatically lowers sex hormone levels in the body. Doctors prescribe it to slow hormone-driven cancers of the prostate and breast, and to relieve pain from endometriosis and uterine fibroids. It has been in widespread clinical use for over three decades.

The scientific side

goserelin is a synthetic decapeptide analogue of naturally occurring gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). Its mechanism of action is paradoxical and dose-dependent: initial administration briefly stimulates pituitary GnRH receptors, causing a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn produces a short-lived spike in sex hormone levels. With continuous administration, however, the sustained receptor occupancy leads to GnRH receptor desensitization and profound downregulation of pituitary gonadotropin secretion. This pituitary downregulation drives LH and FSH levels to profoundly suppressed states, resulting in downstream suppression of gonadal steroidogenesis. In men, serum testosterone falls to castrate levels (less than 2 nmol/L), equivalent to surgical orchidectomy. In women, estradiol and progesterone decline to postmenopausal levels, effectively producing a reversible medical oophorectomy. Goserelin is formulated as a biodegradable subcutaneous depot — a polylactic-glycolic acid (PLGA) copolymer matrix — that releases drug continuously over 28 days (3.6 mg) or approximately 90 days (10.8 mg), maintaining sustained receptor downregulation without daily dosing. Pharmacokinetic studies show rapid absorption from the aqueous solution formulation with an elimination half-life of approximately 4.2 hours in males and 2.3 hours in females; depot formulations release goserelin in a sustained fashion that maintains castrate testosterone concentrations throughout the dosing interval. Recent research has identified direct antitumor effects of GnRH receptor activation in certain cancer tissues. In triple-negative breast cancer, GnRH receptor expression promotes FOS upregulation and subsequent IFI44L transcription, inhibiting cancer cell proliferation, migration, and invasion — goserelin reduced growth of GnRHR-expressing triple-negative breast cancer tumors in a preclinical mouse model. An important clinical caveat of goserelin and all GnRH agonists is the initial testosterone flare during the first one to two weeks of therapy, which can transiently worsen symptoms such as bone pain, urinary obstruction, or spinal cord compression in prostate cancer patients. Co-administration of an antiandrogen for the first weeks of therapy is standard practice to mitigate this flare.

Class: GnRH (LHRH) receptor agonist — synthetic decapeptide; androgen deprivation therapy (ADT) and ovarian suppression agent

What it's studied for

• Palliative treatment of advanced prostate cancer — androgen deprivation therapy (ADT) to castrate testosterone levels Phase III RCT and meta-analysis
• Adjuvant goserelin combined with radiotherapy for locally advanced and localized prostate cancer Phase III RCT
• Adjuvant therapy for premenopausal and perimenopausal women with hormone receptor-positive early breast cancer Phase III RCT
• Treatment of endometriosis — relief of pelvic pain and reduction of endometriotic lesions Phase III RCT
• Ovarian function suppression for pre- and perimenopausal breast cancer — real-world comparison of 3.6 mg monthly versus 10.8 mg quarterly depot formulations Real-world evidence / Phase III non-inferiority
• Direct antitumor activity in triple-negative breast cancer via GnRH receptor signaling Preclinical / Translational
• Ovarian protection during chemotherapy (gonadotoxicity prevention) in women of reproductive age RCT / Systematic review

Safety signals

• Initial testosterone/estrogen flare — transient worsening of hormone-dependent symptoms in the first 1–2 weeks of therapy
• Hot flashes and hypogonadal symptoms (decreased libido, erectile dysfunction in men, vaginal dryness and dyspareunia in women, mood changes, fatigue)
• Bone mineral density loss and increased fracture risk with long-term use
• Gynecomastia and breast tenderness in men
• Injection site reactions — local pain, erythema, bruising, and induration at the subcutaneous implant site
• Erythema nodosum — rare hypersensitivity skin reaction at distant sites
• Cardiovascular metabolic effects — dyslipidemia, insulin resistance, increased fat mass, decreased lean mass, and potential increased cardiovascular event risk with long-term testosterone suppression
• Hepatic steatosis effects — potential modulation of liver fat in women with endometriosis

Community-reported dosing

No peer-reviewed studies indexed for this peptide yet.